SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $288.28M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 0.89M
Average 0.76M
SABS Other Stockholders Equity
Equity items not reported separately, such as additional paid-in capital or treasury stock.
SAB Biotherapeutics, Inc.NASDAQ: SABS
Other Stockholders Equity · Q2 FY2026 · quarter ended Jun 2026
Other stockholders equity remains negative
Q2 FY2026 other stockholders equity was $367.96M, compared with $0 a year earlier.
Context
- Other stockholders equity amounted to 154.5% of total assets at the end of Q2 FY2026, up 154.5 pp from a year earlier.
- Other stockholders equity increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Stockholders Equity history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Other Stockholders Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Stockholders Equity vs competitors
How SABS compares with its peers on the latest reported figures
- SABS's Jun 2026 other stockholders equity of $367.96M is the highest of the 5 companies compared; the peer median is $0.
- Other stockholders equity amounts to 154.5% of total assets for SABS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $367.96M | — | — | 154.5% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | +100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SABS) | $0 | +100.0% | — | 0.0% | |
Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.21M | 15.05M | 56.57M | 8.9M | 10.5M |
| Short-term Investments | 0 | 0 | 0 | 11.86M | 86.09M |
| Net Receivables | 8.01M | 5.56M | 0 | 54.96K | 946.78K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 6.34M | 0 | 0 | 2.98M | 3.51M |
| Total Current Assets | 50.19M | 22.1M | 58.91M | 23.79M | 101.05M |
| Property, Plant & Equipment (Net) | 30.95M | 28.34M | 24.68M | 19.92M | 19.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 46.89M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 467.69K | 350.23K | 482.1K | 5.46M |
| Total Non-current Assets | 30.95M | 28.81M | 25.03M | 20.4M | 71.76M |
| Total Assets | 81.14M | 50.9M | 83.94M | 44.2M | 172.81M |
| Account Payables | 4.46M | 3.68M | 945.93K | 1.69M | 3.15M |
| Short-term Debt | 1.8M | 772.67K | 1.05M | 275.85K | 951.37K |
| Tax Payables | 216.25K | 50K | 40K | 0 | 0 |
| Deferred Revenue | 100K | 0 | 1.32M | 0 | 0 |
| Other Current Liabilities | 8.7M | 8.1M | 4.49M | 0 | 1.55M |
| Total Current Liabilities | 26.46M | 14.99M | 10.81M | 7.98M | 10.68M |
| Long-term Debt | 0 | 541.64K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 10.72M | 320.93K | 11.77M | 6.39M | 5.64M |
| Total Non-current Liabilities | 16.14M | 4.85M | 15.83M | 10.25M | 10.63M |
| Total Liabilities | 42.59M | 19.85M | 26.64M | 18.23M | 21.32M |
| Common Stock | 4.35K | 5.09K | 929 | 935 | 4.77K |
| Retained Earnings | (29.13M) | (47.87M) | (90.06M) | (124.17M) | (110.9M) |
| Accumulated OCI | 0 | 0 | 26.42K | (135.41K) | 186.51K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 38.55M | 31.06M | 57.3M | 25.97M | 151.49M |
| Total Debt | 8.52M | 5.93M | 5.91M | 4.67M | 5.95M |
| Net Debt | (24.69M) | (9.12M) | (50.66M) | (4.23M) | (4.55M) |
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.